Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST):The Dutch GIST Registry Data
BACKGROUND: Patients with unresectable and metastasized gastrointestinal stromal tumor (GIST) experienced a remarkable improvement of progression-free survival (PFS) and overall survival (OS) after the introduction of imatinib. Our hypothesis is that the outcomes of treatment with imatinib are even better nowadays compared with the registration trials that were performed two decades ago. To study this, we used real-life data from a contemporary registry. METHODS: A multicenter, retrospective study was performed by exploring clinical data from a prospective real-life clinical database, the Dutc... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2023 |
Reihe/Periodikum: | Mohammadi , M , IJzerman , N S , Hollander , D D , Bleckman , R F , Oosten , A W , Desar , I M E , Reyners , A K L , Steeghs , N & Gelderblom , H 2023 , ' Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST) : The Dutch GIST Registry Data ' , Targeted oncology , pp. 415–423 . https://doi.org/10.1007/s11523-023-00960-y |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-28619820 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://hdl.handle.net/11370/a5694287-e986-49ce-bd94-8b63f16456cb |